Published 11 hours ago • loading... • Updated 11 hours ago

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

Petrelintide achieves a weight loss of more than 10% which, although lower than that of GLP-1 drugs, also produces fewer side effects

1 Articles

La Razón

Lean Right

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

Petrelintide achieves a weight loss of more than 10% which, although lower than that of GLP-1 drugs, also produces fewer side effects

11 hours ago·Madrid, Spain

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right1Center0Last Updated11 hours agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

La Razón broke the news in Madrid, Spain 11 hours ago on Tuesday, September 29, 2026.

Sources are mostly out of (0)

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

1 Articles

1 Articles

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Two Indian nationals indicted in counterfeit Ozempic smuggling scheme, Justice Department says

Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Most Powerful Obesity Drug yet: People Lost up to 25% of Weight in Trial

Slimming Pens Can Reach SUS with up to 90% Discount, Says MS

Diabetes, Buzzetti (Sid): "Good Results From Combination Insulin and Semaglutide"

Study Finds No Evidence of Harm From GLP-1 Exposure During Pregnancy

Similar News Topics

Similar News Topics

More stories like this

Two Indian nationals indicted in counterfeit Ozempic smuggling scheme, Justice Department says

Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Most Powerful Obesity Drug yet: People Lost up to 25% of Weight in Trial

Slimming Pens Can Reach SUS with up to 90% Discount, Says MS

Diabetes, Buzzetti (Sid): "Good Results From Combination Insulin and Semaglutide"

Study Finds No Evidence of Harm From GLP-1 Exposure During Pregnancy

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

1 Articles

1 Articles

Translate IconThe New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Two Indian nationals indicted in counterfeit Ozempic smuggling scheme, Justice Department says

Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Most Powerful Obesity Drug yet: People Lost up to 25% of Weight in Trial

Slimming Pens Can Reach SUS with up to 90% Discount, Says MS

Diabetes, Buzzetti (Sid): "Good Results From Combination Insulin and Semaglutide"

Study Finds No Evidence of Harm From GLP-1 Exposure During Pregnancy

Similar News Topics

Similar News Topics

More stories like this

Two Indian nationals indicted in counterfeit Ozempic smuggling scheme, Justice Department says

Amylin Obesity Drug from Zealand Pharma Succeeds at Phase II

Most Powerful Obesity Drug yet: People Lost up to 25% of Weight in Trial

Slimming Pens Can Reach SUS with up to 90% Discount, Says MS

Diabetes, Buzzetti (Sid): "Good Results From Combination Insulin and Semaglutide"

Study Finds No Evidence of Harm From GLP-1 Exposure During Pregnancy

The New Antiobesity Drug that Is Presented as an Alternative to the Ozempic Type

Bias Distribution

Factuality